Axsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Acquired by BNP Paribas Financial Markets

BNP Paribas Financial Markets raised its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 71.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 13,733 shares of the company's stock after purchasing an additional 5,737 shares during the quarter. BNP Paribas Financial Markets' holdings in Axsome Therapeutics were worth $1,234,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of AXSM. Arizona State Retirement System increased its holdings in Axsome Therapeutics by 2.1% in the second quarter. Arizona State Retirement System now owns 8,630 shares of the company's stock valued at $695,000 after buying an additional 177 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Axsome Therapeutics by 22.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,736 shares of the company's stock worth $156,000 after buying an additional 318 shares during the period. Northwestern Mutual Wealth Management Co. acquired a new stake in Axsome Therapeutics during the second quarter valued at approximately $27,000. WCM Investment Management LLC increased its position in Axsome Therapeutics by 0.3% in the 3rd quarter. WCM Investment Management LLC now owns 113,692 shares of the company's stock valued at $10,191,000 after acquiring an additional 347 shares during the period. Finally, US Bancorp DE boosted its stake in Axsome Therapeutics by 0.3% during the 3rd quarter. US Bancorp DE now owns 133,126 shares of the company's stock valued at $11,964,000 after purchasing an additional 421 shares in the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AXSM. Wells Fargo & Company initiated coverage on Axsome Therapeutics in a research report on Tuesday, September 3rd. They issued an "overweight" rating and a $140.00 price target on the stock. HC Wainwright restated a "buy" rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $107.00 target price on shares of Axsome Therapeutics in a report on Monday, September 16th. StockNews.com raised shares of Axsome Therapeutics from a "sell" rating to a "hold" rating in a research note on Wednesday, November 20th. Finally, Royal Bank of Canada boosted their target price on shares of Axsome Therapeutics from $130.00 to $131.00 and gave the company an "outperform" rating in a report on Friday, October 4th. One research analyst has rated the stock with a hold rating and fourteen have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $124.93.

Axsome Therapeutics Stock Down 0.9 %

Shares of AXSM traded down $0.95 during trading hours on Tuesday, hitting $98.82. The stock had a trading volume of 390,534 shares, compared to its average volume of 611,410. The firm has a market capitalization of $4.79 billion, a P/E ratio of -15.13 and a beta of 1.18. The company has a debt-to-equity ratio of 1.97, a current ratio of 2.44 and a quick ratio of 2.37. Axsome Therapeutics, Inc. has a 1-year low of $64.11 and a 1-year high of $105.00. The firm has a 50 day simple moving average of $92.80 and a 200-day simple moving average of $87.08.

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($1.34) EPS for the quarter, beating analysts' consensus estimates of ($1.38) by $0.04. Axsome Therapeutics had a negative net margin of 91.87% and a negative return on equity of 158.36%. The firm had revenue of $104.76 million during the quarter, compared to analyst estimates of $98.71 million. During the same period in the previous year, the business earned ($1.32) EPS. Sell-side analysts predict that Axsome Therapeutics, Inc. will post -4.6 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Mark E. Saad sold 11,016 shares of the firm's stock in a transaction on Wednesday, September 11th. The shares were sold at an average price of $91.31, for a total transaction of $1,005,870.96. Following the completion of the transaction, the director now directly owns 10,002 shares of the company's stock, valued at approximately $913,282.62. This trade represents a 52.41 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 22.40% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.